Literature DB >> 25348528

Activities of antibiotic combinations against resistant strains of Pseudomonas aeruginosa in a model of infected THP-1 monocytes.

Julien M Buyck1, Paul M Tulkens1, Françoise Van Bambeke2.   

Abstract

Antibiotic combinations are often used for treating Pseudomonas aeruginosa infections but their efficacy toward intracellular bacteria has not been investigated so far. We have studied combinations of representatives of the main antipseudomonal classes (ciprofloxacin, meropenem, tobramycin, and colistin) against intracellular P. aeruginosa in a model of THP-1 monocytes in comparison with bacteria growing in broth, using the reference strain PAO1 and two clinical isolates (resistant to ciprofloxacin and meropenem, respectively). Interaction between drugs was assessed by checkerboard titration (extracellular model only), by kill curves, and by using the fractional maximal effect (FME) method, which allows studying the effects of combinations when dose-effect relationships are not linear. For drugs used alone, simple sigmoidal functions could be fitted to all concentration-effect relationships (extracellular and intracellular bacteria), with static concentrations close to (ciprofloxacin, colistin, and meropenem) or slightly higher than (tobramycin) the MIC and with maximal efficacy reaching the limit of detection in broth but only a 1 to 1.5 (colistin, meropenem, and tobramycin) to 2 to 3 (ciprofloxacin) log10 CFU decrease intracellularly. Extracellularly, all combinations proved additive by checkerboard titration but synergistic using the FME method and more bactericidal in kill curve assays. Intracellularly, all combinations proved additive only based on both FME and kill curve assays. Thus, although combinations appeared to modestly improve antibiotic activity against intracellular P. aeruginosa, they do not allow eradication of these persistent forms of infections. Combinations including ciprofloxacin were the most active (even against the ciprofloxacin-resistant strain), which is probably related to the fact this drug was the most effective alone intracellularly.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25348528      PMCID: PMC4291360          DOI: 10.1128/AAC.04011-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  47 in total

1.  In vitro activities of ceftobiprole combined with amikacin or levofloxacin against Pseudomonas aeruginosa: evidence of a synergistic effect using time-kill methodology.

Authors:  Michael Kresken; Barbara Körber-Irrgang; Jörg Läuffer; Sabine Decker-Burgard; Todd Davies
Journal:  Int J Antimicrob Agents       Date:  2011-04-22       Impact factor: 5.283

2.  FlhA, a component of the flagellum assembly apparatus of Pseudomonas aeruginosa, plays a role in internalization by corneal epithelial cells.

Authors:  S M Fleiszig; S K Arora; R Van; R Ramphal
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

3.  Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.

Authors:  Glenn A Pankuch; Gengrong Lin; Harald Seifert; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-10-29       Impact factor: 5.191

4.  Pseudomonas aeruginosa acquires biofilm-like properties within airway epithelial cells.

Authors:  Raquel Garcia-Medina; W Michael Dunne; Pradeep K Singh; Steven L Brody
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

Review 5.  Antibiotic combinations: should they be tested?

Authors:  G M Eliopoulos; C T Eliopoulos
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

6.  Synergy assessed by checkerboard. A critical analysis.

Authors:  M H Hsieh; C M Yu; V L Yu; J W Chow
Journal:  Diagn Microbiol Infect Dis       Date:  1993 May-Jun       Impact factor: 2.803

7.  Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: study of antibiotic combinations.

Authors:  Hoang Anh Nguyen; Olivier Denis; Anne Vergison; Paul M Tulkens; Marc J Struelens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

8.  Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa.

Authors:  D M Cappelletty; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

9.  Pharmacodynamic effects of extended dosing intervals of imipenem alone and in combination with amikacin against Pseudomonas aeruginosa in an in vitro model.

Authors:  B J McGrath; K C Lamp; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

Review 10.  Clinical utility of synergy testing for multidrug-resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis: 'the motion for'.

Authors:  Lisa Saiman
Journal:  Paediatr Respir Rev       Date:  2007-06-05       Impact factor: 2.726

View more
  6 in total

1.  Simultaneous Particle Size Reduction and Homogeneous Mixing to Produce Combinational Powder Formulations for Inhalation by the Single-Step Co-Jet Milling.

Authors:  Junhong Ling; Sharad Mangal; Heejun Park; Shaoning Wang; Alex Cavallaro; Qi Tony Zhou
Journal:  J Pharm Sci       Date:  2019-05-18       Impact factor: 3.534

2.  Co-Delivery of Ciprofloxacin and Colistin in Liposomal Formulations with Enhanced In Vitro Antimicrobial Activities against Multidrug Resistant Pseudomonas aeruginosa.

Authors:  Shaoning Wang; Shihui Yu; Yuwei Lin; Peizhi Zou; Guihong Chai; Heidi H Yu; Hasini Wickremasinghe; Nivedita Shetty; Junhong Ling; Jian Li; Qi Tony Zhou
Journal:  Pharm Res       Date:  2018-08-09       Impact factor: 4.200

3.  Improved Physical Stability and Aerosolization of Inhalable Amorphous Ciprofloxacin Powder Formulations by Incorporating Synergistic Colistin.

Authors:  Nivedita Shetty; Patricia Ahn; Heejun Park; Sonal Bhujbal; Dmitry Zemlyanov; Alex Cavallaro; Sharad Mangal; Jian Li; Qi Tony Zhou
Journal:  Mol Pharm       Date:  2018-08-03       Impact factor: 4.939

4.  Evaluation of co-delivery of colistin and ciprofloxacin in liposomes using an in vitro human lung epithelial cell model.

Authors:  Guihong Chai; Heejun Park; Shihui Yu; Fanfan Zhou; Jian Li; Qingguo Xu; Qi Tony Zhou
Journal:  Int J Pharm       Date:  2019-08-12       Impact factor: 5.875

5.  RX-P873, a Novel Protein Synthesis Inhibitor, Accumulates in Human THP-1 Monocytes and Is Active against Intracellular Infections by Gram-Positive (Staphylococcus aureus) and Gram-Negative (Pseudomonas aeruginosa) Bacteria.

Authors:  Julien M Buyck; Frédéric Peyrusson; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2015-05-26       Impact factor: 5.191

6.  An LC-MS/MS method for simultaneous analysis of the cystic fibrosis therapeutic drugs colistin, ivacaftor and ciprofloxacin.

Authors:  Huiya Yuan; Shihui Yu; Guihong Chai; Junting Liu; Qi Tony Zhou
Journal:  J Pharm Anal       Date:  2021-02-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.